Premium
Long‐term therapy with deflazacort decreases myocardial fibrosis in mdx mice
Author(s) -
Marques Maria Julia,
Oggiam Daniella Silva,
Barbin Isabel Cristina Chagas,
Ferretti Renato,
Santo Neto Humberto
Publication year - 2009
Publication title -
muscle and nerve
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 145
eISSN - 1097-4598
pISSN - 0148-639X
DOI - 10.1002/mus.21341
Subject(s) - deflazacort , medicine , fibrosis , dystrophin , myocardial fibrosis , mdx mouse , gastroenterology , endocrinology , duchenne muscular dystrophy , cardiology , pathology , surgery
We evaluated the effects of long‐term administration of deflazacort (DFZ) on the progression of myocardial fibrosis in mdx mice. Mdx mice (6 months old) were treated with DFZ for 15 months. Myocardial fibrosis (MF) was evaluated by histomorphometric methods, and treated and untreated mdx mice of the same age (21 months) were compared. DFZ significantly decreased MF. We conclude that long‐term therapy with DFZ is effective in slowing down the progression of fibrosis in the dystrophin‐deficient heart. Muscle Nerve, 2009